On March 24, 2026, the expert team consisting of Professor Wang Guangwei, Dean of the School of Medical Information and Engineering at Hunan University of Medicine, Professor Yan Shouchun, and Dr. Yi Sili from Huaihua University, visited our company for an in-depth inspection and exchange. As a pioneer and leader in the field of sponge microneedle (hydrolyzed sponge) technology, our company fully demonstrated to the expert team the whole-chain innovation capability from basic research to industrialization. Both parties conducted strategic-level dialogue around the medical translation prospects of this technology. The experts highly recognized our company's technical strength and industrial vision, and unanimously agreed to accelerate the promotion of substantive industry-academia-research cooperation, jointly opening up new tracks for transdermal delivery technology in the medical health field.
I. Expert Team: Top Interdisciplinary Think Tank, Empowering Technological Upgrading
The expert combination visiting this time combines profound academic accumulation, cutting-edge scientific vision, and rich clinical experience. Their research directions are highly complementary to our core technology:
Professor Wang Guangwei (Team Leader): As the dean of a large medical school overseeing more than 3,500 students, a doctoral supervisor in neurosurgery, and a hospital administrator, he is not only an authority in central nervous system disease research, but also an active promoter of interdisciplinary innovation. His grasp of biomedical frontier trends and deep understanding of clinical demand translation provide crucial strategic guidance for sponge microneedle technology to enter blue ocean markets such as neuro-drug targeted delivery and high-end medical materials.
Dr. Yi Sili: With a bioengineering research background from Harvard University Medical School, specializing in 3D printed hydrogels and intelligent biomaterials. His profound foundation in surface and interface chemistry and successful experience in fine chemical industrialization directly address the core bottlenecks of sponge microneedle technology in new material synthesis, precise structural regulation, and large-scale production. He is an ideal academic partner to promote our company's products to upgrade to next-generation intelligent and functional drug-loaded systems.
Professor Yan Shouchun, Chief Physician of the First Affiliated Hospital of Hunan University of Medicine: This emergency and critical care and trauma medicine expert from a top-tier medical institution has presided over multiple national, provincial, and ministerial-level research projects, and has considerable achievements in complex wound repair and life support fields. His participation provides an extremely precious and authoritative "clinical gold standard" perspective for the clinical verification and application expansion of sponge microneedle technology in high-end medical scenarios such as severe trauma dressings, local immune regulation, and tumor interventional therapy.
II. Company Strength and Product Advantages: Building Core Barriers, Leading Industry Innovation
During the exchange, our company systematically presented to the expert team the solid foundation and excellent performance of our product matrix as a technology-driven enterprise in the industry:
Independent and Controllable Core Technology: Our company possesses completely independent intellectual property rights for sponge microneedles (hydrolyzed sponge), and has built a full set of patent barriers from core matrix material synthesis, micro-nano structure precision molding, to active ingredient loading and controlled release technology. With their unique biodegradable property, excellent mechanical support structure, and powerful drug-loading capacity, the products have achieved revolutionary breakthroughs in transdermal drug delivery efficiency and user comfort.
Industry-Leading R&D Platform: We have established an international-standard R&D and Evaluation Center, covering the functions of materials science, formulation science, dermatology, and preliminary pre-clinical research. The platform can efficiently complete a series of key studies such as material compatibility, drug release kinetics, skin permeability, and efficacy verification, ensuring scientific rigor and efficient iteration of product R&D.
Broad Layout of Application Fields: Currently, our sponge microneedle technology has been successfully applied in the field of functional skincare products, and is carrying out forward-looking layout in the medical device direction. The significant effects of the products in promoting transdermal absorption of active ingredients and achieving precise repair have been widely verified by the market. We are actively expanding it to broader medical health scenarios such as post-operative repair, chronic wound treatment, transdermal immunity, and local drug delivery.
III. In-Depth Exchange and Strategic Consensus: From Technical Recognition to Cooperation Implementation
After deeply visiting the R&D center and production lines, and listening to detailed technical reports, the expert team gave extremely high evaluations to our company's technical innovation capability, quality management system, and industrialization achievements. Dean Wang Guangwei pointed out: "Your company's deep cultivation in sponge microneedle technology has successfully opened up the critical path from laboratory concept to mature products. Its technical advancement and engineering capability are impressive."
Both parties conducted several hours of closed-door seminars around issues such as "clinical demand-oriented product definition," "joint R&D targeting specific indications (such as local treatment of brain diseases, diabetic foot ulcers)," and "pre-clinical research schemes compliant with medical device regulations," and formed multiple specific consensuses.
IV. Co-Drawing the Future: Signing Cooperation Intent, Opening a New Stage
Starting from this, both parties decided to establish a long-term, close strategic cooperative partnership, and preliminarily formulated the following cooperation directions:
Co-building "High-end Transdermal Delivery Technology Joint Laboratory": Integrate our industrialization platform and the university's clinical research resources to jointly tackle next-generation intelligently responsive sponge microneedle materials.
Jointly Applying for National Key R&D Projects: Targeting local treatment demands for major diseases (such as tumors, non-healing wounds), jointly apply for provincial/ministerial-level and above science and technology projects.
Promoting Clinical Research and Product Registration Cooperation: Relying on the clinical resources of the Affiliated Hospital of Hunan University of Medicine, jointly carry out clinical trials and evidence accumulation for products used in medical scenarios, accelerating the registration process for Class II and Class III medical devices.
Co-building Talent Training and Cultivation Base: Dispatch high-level R&D and clinical registration talent for our company, while providing industrial practice and research topic platforms for college students.
This visit is not only a collision of top academic ideas and leading industrial technology, but also marks that China's sponge microneedle technology development has entered a new stage of deep "industry-academia-research-medicine" integration and collaborative innovation. Our company will continue to uphold the concept of open cooperation, and work with Hunan University of Medicine to build sponge microneedle technology into a benchmark solution serving human health.
